ENANTA PHARMACEUTICALS, INC.

(ENTA)
  Report
Delayed Nasdaq  -  04:00 2022-08-11 pm EDT
66.49 USD   -2.06%
08/10Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $59 From $53, Maintains Perform Rating
MT
08/09JMP Securities Raises Enanta Pharmaceuticals' Price Target to $137 From $103, Maintains Market Outperform Rating
MT
08/08ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL THIRD QUARTER ENDED JUNE 30, 2022 WITH WEBCAST AND CONFERENCE CALL TODAY AT 4 : 30 p.m. ET - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Enanta Pharmaceuticals Files Patent Lawsuit Against Pfizer Over COVID-19 Antiviral -- Shares Jump in Pre-Market

06/22/2022 | 07:18am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ENANTA PHARMACEUTICALS, INC. -2.06% 66.49 Delayed Quote.-11.09%
PFIZER, INC. -3.32% 48.29 Delayed Quote.-18.22%
All news about ENANTA PHARMACEUTICALS, INC.
08/10Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $59 From $53, Maintains Perf..
MT
08/09JMP Securities Raises Enanta Pharmaceuticals' Price Target to $137 From $103, Maintains..
MT
08/08ENANTA PHARMACEUTICALS REPORTS FINAN : 30 p.m. ET - Form 8-K
PU
08/08ENANTA PHARMACEUTICALS : Fiscal Q3 Earnings Snapshot
AQ
08/08TRANSCRIPT : Enanta Pharmaceuticals, Inc., Q3 2022 Earnings Call, Aug 08, 2022
CI
08/08ENANTA PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
08/08Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
08/08Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q3 Revenue $19.5M
MT
08/08ENANTA PHARMACEUTICALS REPORTS FINAN : 30 p.m. ET
BU
08/08Enanta Pharmaceuticals, Inc. Announces Appointment of Scott T. Rottinghaus to the Posit..
CI
More news
Analyst Recommendations on ENANTA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 89,0 M - -
Net income 2022 -123 M - -
Net Debt 2022 - - -
P/E ratio 2022 -11,1x
Yield 2022 -
Capitalization 1 377 M 1 377 M -
Capi. / Sales 2022 15,5x
Capi. / Sales 2023 9,15x
Nbr of Employees 155
Free-Float 93,8%
Chart ENANTA PHARMACEUTICALS, INC.
Duration : Period :
Enanta Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENANTA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 66,49 $
Average target price 77,67 $
Spread / Average Target 16,8%
EPS Revisions
Managers and Directors
Jay R. Luly President, Chief Executive Officer & Director
Paul J. Mellett CFO & Senior VP-Finance & Administration
Bruce Leonard Andrews Carter Non-Executive Chairman
Yat Sun Or CSO, Senior Vice President-Research & Development
Terry C. Vance Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENANTA PHARMACEUTICALS, INC.-11.09%1 377
MODERNA, INC.-32.35%67 212
LONZA GROUP AG-25.18%46 073
IQVIA HOLDINGS INC.-14.23%45 135
SEAGEN INC.12.57%32 099
ALNYLAM PHARMACEUTICALS, INC.35.27%27 533